Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed · Phase 1

Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of topotecan plus etoposide in treating patients who have recurrent ovarian cancer, peritoneal cancer, or fallopian tube cancer.

Key facts

Study ID

NCT00003967

Run by

Gynecologic Oncology Group

People needed

24

Starts

1999-09-01

Last updated by the study team

2013-05-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Holden Comprehensive Cancer Center at The University of Iowa — Iowa City, Iowa, United States
• Mercy Medical Center, Inc. — Baltimore, Maryland, United States
• Cooper Hospital/University Medical Center — Camden, New Jersey, United States
• Ireland Cancer Center — Cleveland, Ohio, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.